A nurse died.
That single event snapped the alarm bell for health officials. Something dangerous was moving through the Democratic Republic of the Congo. It wasn’t Ebola. Not exactly. It was the Bundibugyo virus. Rare. Deadly. And right now, it is testing a system that simply isn’t prepared.
Boston University virologist Nancy Sullivan sees this clearly. In a recent New England Journal of Medicine review, she argues we have a habit of ignoring threats that don’t make the evening news until it’s too late.
The current outbreak in the DRC and Uganda has already outpaced every previous record. Two earlier outbreaks—one in Uganda in 2007, another in the DRC in 2012—were minor compared to what we’re seeing now.
The World Health Organization confirmed 695 cases as of June 11, 2026.
138 of them died.
The problem with slow tests
Stopping a virus requires speed.
Sullivan explains that the response chain is fragile. You need to identify the sick, separate them from the healthy, trace every contact, and enforce strict infection controls. Break any link in that chain and the virus slips through.
The biggest bottleneck? Testing.
Bundibugyo looks like malaria early on. It looks like typhoid. It mimics several common tropical diseases. You cannot guess it based on symptoms. You need a lab.
The DRC lacks local capacity. Samples must travel far. Often to national reference laboratories equipped to handle dangerous pathogens. That travel takes time. Days. Sometimes weeks.
“Delays in specimen collection, transportation, and testing can postpone confirmation… which hinders isolation… and the initiation of outbreak control measures,” Sullivan wrote.
While those samples sit on a truck, the virus spreads. It spreads to families. It spreads to caregivers.
This isn’t abstract theory. It caused real harm here. A nurse contracted the virus inside a hospital setting, died from it, and that death officially signaled the scale of the 2026 crisis. Bundibugyo is a filovirus—cousin to Ebola, Marburg, and Sudan. It causes hemorrhagic fever. Widespread inflammation. Bleeding. Organ failure. Direct contact with bodily fluids kills you if you aren’t protected.
Preparedness blind spots
Why did we catch this so late?
Most preparedness planning focuses on the likely suspects. The pathogens with big headlines. Bundibugyo doesn’t usually make them.
Sullivan calls this a blind spot. After decades of silence, the virus returned. We predicted the next big one would be different. It wasn’t.
There are no licensed vaccines specifically for Bundibugyo. Treatments don’t exist. There is hope that vaccines for Ebola or Marburg might offer cross-protection, but hope is not a strategy.
Researchers have made headway with other filoviruses. Bundibugyo lags behind because it occurs less frequently. Why invest in a threat that barely appears?
The question remains.
Are we going to keep waiting for neglected diseases to spread widely before we build operational readiness?
Sullivan wants more than just new diagnostics or experimental shots. She wants multinational operational plans ready for any severe virus, not just the ones trending on social media.
We have the tools to see the problem.
Now we need the will to fix it.
Or we will find out the hard way next time.
Reference: “Bundibugyo Virus Disease: 2026 Clinical and Public Health Responses”, N Engl J Med, 23 June 20
